Mayo Clinic researchers are tracking the familiar characteristics of kidney stone formers in an online prediction tool that could help sufferers anticipate if they’ll experience future episodes.
John Lieske, M.D., gives an overview of the phospholipase A2 receptor antibodies testing available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.
There have been concerns in the U.S. recently about the possible harmful side effects from absorbing gadolinium-based contrast agents into the body during some MRI exams. To address some of the anxiety and concerns over this issue, Paul Jannetto, Ph.D., DABCC, FAACC, and Joshua Bornhorst, Ph.D., DABCC, FAACC, Co-Directors of the Mayo Clinic Metals Laboratory and leading experts in this field, have compiled the following list of the most up-to-date information.
The National Kidney Foundation, the American Society for Clinical Pathology, and the nation’s leading laboratories and clinical laboratory societies have announced a new collaboration to remove barriers to testing for chronic kidney disease.
A team of Mayo Clinic pathologists have discovered a new tissue biomarker, DNAJB9, for fibrillary glomerulonephritis, a rare kidney disease of unknown pathogenesis and poor outlook—nearly half of all patients end up on dialysis within four years of diagnosis.
Recently, a team of researchers and physicians at Mayo Clinic in Rochester identified a new type of renal amyloidosis derived from the protein apolipoprotien C-II (Apo-CII).
The National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) provide guidelines for surveillance after surgery for renal cell carcinoma (RCC). In a recent study in the Journal of Clinical Oncology, Mayo Clinic researchers assess the ability of the guidelines to capture RCC recurrences after surgery when abiding by the prescribed protocols.